CN102784237B - Pharmaceutical composition for preventing or treating diabetic complications - Google Patents
Pharmaceutical composition for preventing or treating diabetic complications Download PDFInfo
- Publication number
- CN102784237B CN102784237B CN201110127492.7A CN201110127492A CN102784237B CN 102784237 B CN102784237 B CN 102784237B CN 201110127492 A CN201110127492 A CN 201110127492A CN 102784237 B CN102784237 B CN 102784237B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- radix
- diabetic
- ligustri lucidi
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a pharmaceutical composition for preventing or treating diabetic complications, which relates to six traditional Chinese medicines, and has definite and obvious curative effect on treating diabetic nephropathy and diabetic retinopathy.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to the pharmaceutical composition of a kind of prevention or treatment diabetic complication.
Background technology
Diabetes are common frdquently encountered diseases of serious harm human health, are the third-largest diseases being only second to cancer and cardiovascular disease.Carbohydrate metabolism disturbance caused by diabetes, causes microangiopathies, then causes a series of diabetic complication, comprises retinopathy, diabetic nephropathy and diabetes foot disease etc.The mechanism of diabetic microvascular complication is still not exclusively clear and definite, think the formation of non-enzymatic advanced glycation end products, the activation of Protein kinase C (PKC) signal path, response to oxidative stress at present, wherein PKC can impel VEGF (VEGF) to express, thus promote that new vessels is formed, increase vascular permeability; Wherein PKC-β mainly expresses in the tissues such as retina, kidney, heart, brain and islets of langerhans, be considered to closely-related a kind of main hypotype [TurtleKR with diabetic microvascular complication, BakrisGL, TotoRD, etal.Theeffectofruboxistaurinonnephropathyintype2diabete s.DiabetesCare, 2005,28 (11): 2686-2690].
Wherein diabetic nephropathy (diabeticnephropathy, DN), diabetic renal papillary necrosis (diabeticretinopathy, DR) are the complication that diabetes are common and serious.Diabetic nephropathy sickness rate be 16.8-23.48% [Han Xiaoliang, Chi Zhisheng etc., to the research of non-insulin-dependent diabetes mellitus nephropathy, Chinese Journal of Nephrology, 1989; (5): 134 and Liu Wenqin etc., Clinical Analysis on 58 Cases of Diabetic Nephropathy, Chinese Journal of Nephrology, 1986; (2): 304].Once there is nephropathy in diabetic, occur persistence urine protein, then the state of an illness develops gradually, and in Progressive symmetric erythrokeratodermia, development is until renal failure, and the mortality rate of diabetic nephropathy is 17 times of Non-diabetic nephropathy.Diabetic retinopathy is a series of retinopathy that the retinal circulation caused due to diabetics carbohydrate metabolism disturbance causes extremely.Lose in the basement membrane thickened of the early stage capillary endothelial cell of pathological changes, pericyte, blood capillary automatic regulation function loses compensatory, inner skin cell function infringement subsequently, blood constituent oozes out, and blood capillary is inaccessible.Due to retinal ischemia widely, cause retinal edema and new vessels to be formed, concurrent vitreous hemorrhage, lead many complication such as holder property detachment of retina, cause visual deterioration even blind [international ophthalmology magazine, in January, 2011, the 11st volume, 1st phase, 103-105].The incidence rate of diabetic renal papillary necrosis generally after diabetics is fallen ill 5 years is increase to 60% after 25%, 10 years, can up to 75% ~ 80% after 15 years.Therefore, the control of DR receives much concern [Heilungkiang medical science, the 34th volume, the 9th phase, 671-673 in 2010] in treating diabetes always.
CN1347714A discloses a kind of pharmaceutical composition for the treatment of diabetic nephropathy, is made up of the Radix Astragali, Fructus Ligustri Lucidi, Hirudo, Radix Et Rhizoma Rhei, Radix Pseudostellariae, Fructus Lycii.Applicant is known carry out large quantity research again on the basis of original prescription after, by carrying out prescription again to crude drug wherein, obtain the pharmaceutical composition can treating diabetic complication, pharmaceutical composition of the present invention especially treatment diabetic nephropathy and diabetic renal papillary necrosis in determined curative effect obvious.
Summary of the invention
One of the object of the invention is the pharmaceutical composition providing a kind of prevention or treatment diabetic complication, and wherein active component is made up of the crude drug of following percentage by weight: the Radix Astragali 32 ~ 40%, Radix Pseudostellariae 10 ~ 15%, Fructus Ligustri Lucidi 16 ~ 20%, Fructus Lycii 12 ~ 18%, Hirudo 11 ~ 13%, Radix Et Rhizoma Rhei 5 ~ 8%; Be preferably the Radix Astragali 36.14%, Radix Pseudostellariae 12.05%, Fructus Ligustri Lucidi 18.07%, Fructus Lycii 14.46%, Hirudo 12.05%, Radix Et Rhizoma Rhei 7.23%.
Diabetic complication described above is preferably diabetic nephropathy or diabetic renal papillary necrosis; Described diabetic renal papillary necrosis is more preferably early diabetic retinopathy.
Aforementioned pharmaceutical compositions can make powder, tablet, capsule, pill, oral liquid, granule.
Present invention also offers the preparation method of aforementioned pharmaceutical compositions, concrete steps are as follows:
1. Radix Astragali removing impurity, size separately, is cleaned, is run through, be cut into 2-4mm sheet, 60-80 DEG C of dry for standby;
2. Radix Pseudostellariae removing impurity, wash quickly is clean, is cut into 2-4mm sheet, 60-80 DEG C of dry for standby;
3. Fructus Ligustri Lucidi removing impurity and stalk leaf, clean, 60-80 DEG C of drying, the used time smashs to pieces;
4. Fructus Lycii removing impurity, picks carpopodium, for subsequent use after clean and tidy;
5. Hirudo, cleans, cutting, 60-70 DEG C of dry for standby;
6. Radix Et Rhizoma Rhei, removing impurity, clean, run through, cut straight sheet, thickness is 2-4mm, 60-80 DEG C of oven dry, and sieve goes chip for subsequent use;
Radix Et Rhizoma Rhei after being concocted by said method is pulverized, and cross 100 mesh sieves, get fine powder and carry out radiation sterilization, 2KGY/ hour, exposure time is for subsequent use after 3 hours; The Fructus Ligustri Lucidi that said method of learning from else's experience was concocted adds 6 times and measures 75% ethanol, reflux, extract, 2-4 time, each 1 hour, ethanol is reclaimed in alcohol extraction; The medicinal residues of Fructus Ligustri Lucidi and the Radix Astragali concocted through said method, Radix Pseudostellariae, Fructus Lycii, Hirudo add water the water of 6 times amount, decoct 2-4 time, each 2 hours, filter, merge Aqueous extracts, go to abandon medicinal residues, the concentrated solution after fried liquid and Fructus Ligustri Lucidi reclaim ethanol merges, under-0.015-0.030MPa, concentrating under reduced pressure, temperature is 80 DEG C, when to be concentrated into extractum relative density be 1.05-1.15, at 70 DEG C, spraying dry is dried cream powder, then mixes with aforementioned Radix Et Rhizoma Rhei for subsequent use and get final product.
Compared with prior art, its advantage is pharmaceutical composition of the present invention:
The complication that pharmaceutical composition of the present invention can effectively be treated or diabetes-alleviating causes, particularly have obvious curative effect to diabetic nephropathy and diabetic renal papillary necrosis, determined curative effect, onset time is short.
Accompanying drawing explanation
1, medicine Contained Serum extract of the present invention on the impact of the Rat Mesangial PKC-β I protein kinase of high sugar induction (organize with height sugar and compares:
*p < 0.05,
*p < 0.01)
2, the present invention be about thing Contained Serum extract on the impact of the Rat Mesangial PKC-β II protein kinase of high sugar induction (compare with height sugar group,
*p < 0.05,
*p < 0.01)
3, medicine Contained Serum extract of the present invention on the impact of the HBZY-1 emiocytosis VEGF of high sugar induction (compare with height sugar group,
*p < 0.05,
*p < 0.01)
4, medicine Contained Serum extract of the present invention on the impact of the HBZY-1 emiocytosis TGF-β 1 of high sugar induction (compare with height sugar group,
*p < 0.05,
*p < 0.01)
Comparative example
Comparative example 1
Prepare by CN1347714A embodiment 1 method
Comparative example 2
Prepare by CN1347714A embodiment 2 method
Comparative example 3
Prepare by CN1347714A embodiment 3 method
Detailed description of the invention
Embodiment 1
Radix Astragali 540g, Radix Pseudostellariae 180g, Fructus Ligustri Lucidi 270g,
Fructus Lycii 216g, Hirudo 180g, Radix Et Rhizoma Rhei 108g
First said medicine carries out the process of preparing Chinese medicine of Chinese crude drug:
1) Radix Astragali removing impurity, size separately, is cleaned, is run through, be cut into 2-4mm sheet, 60-80 DEG C of dry for standby;
2) Radix Pseudostellariae removing impurity, wash quickly is clean, is cut into 2-4mm sheet, 60-80 DEG C of dry for standby;
3) Fructus Ligustri Lucidi removing impurity and stalk leaf, clean, 60-80 DEG C of drying, the used time smashs to pieces;
4) Fructus Lycii removing impurity, picks carpopodium, for subsequent use after clean and tidy;
5) Hirudo, cleans, cutting, 60-70 DEG C of dry for standby;
6) Radix Et Rhizoma Rhei, removing impurity, clean, run through, cut straight sheet, thickness is 2-4mm, 60-80 DEG C of oven dry, and sieve goes chip for subsequent use;
Radix Et Rhizoma Rhei after being concocted by said method is pulverized, and cross 100 mesh sieves, get fine powder and carry out radiation sterilization, 2KGY/ hour, exposure time is for subsequent use after 3 hours; The Fructus Ligustri Lucidi that said method of learning from else's experience was concocted adds 6 times and measures 75% ethanol, reflux, extract, 2-4 time, each 1 hour, ethanol is reclaimed in alcohol extraction; The medicinal residues of Fructus Ligustri Lucidi and the Radix Astragali concocted through said method, Radix Pseudostellariae, Fructus Lycii, Hirudo add water the water of 6 times amount, decoct 2-4 time, each 2 hours, filter, merge Aqueous extracts, go to abandon medicinal residues, the concentrated solution after fried liquid and Fructus Ligustri Lucidi reclaim ethanol merges, under-0.015-0.030MPa, concentrating under reduced pressure, temperature is 80 DEG C, when to be concentrated into extractum relative density be 1.05-1.15, at 70 DEG C, spraying dry is dried cream powder, then mixes to obtain pharmaceutical composition with aforementioned Radix Et Rhizoma Rhei for subsequent use.
Embodiment 2
Get the crude drug of following weight percentage:
The Radix Astragali 32%, Radix Pseudostellariae 15%, Fructus Ligustri Lucidi 20%,
Fructus Lycii 12%, Hirudo 13%, Radix Et Rhizoma Rhei 8%
It concocts basic identical with embodiment 1 with preparation method.
Embodiment 3
Get the crude drug of following weight percentage:
The Radix Astragali 40%, Radix Pseudostellariae 10%, Fructus Ligustri Lucidi 16%,
Fructus Lycii 18%, Hirudo 11%, Radix Et Rhizoma Rhei 5%
It concocts basic identical with embodiment 1 with preparation method.
Embodiment 4: the preparation of powder
Example 1 obtains pharmaceutical composition, and cross 100 mesh sieves, bag seal, 2g/ bag is powder finished product.
Embodiment 5: the preparation of capsule
Example 1 obtains pharmaceutical composition, makes granule, dry, adds pregelatinized Starch, Pulvis Talci is appropriate, be mixed, incapsulate, make 1000.
Embodiment 6: the preparation of pill
Example 2 obtains pharmaceutical composition, and at 60 DEG C, drying 1 hour, pulverizes, and crosses 60 mesh sieves, uses pure water pill, and every 20 the heavy 1g of the watered pill, coating, polishing, 60 DEG C of dryings are pill finished product.
Embodiment 7: the preparation of tablet
Example 3 obtains pharmaceutical composition, adds supplementary product starch 10%, and mixing, makes granule, and drying 1 hour at 60 DEG C, tabletting, sheet weight: 0.5g/ sheet, film coating is tablet finished product.
Embodiment 8 medicine of the present invention is on the impact of the HBZY-1 cell PKC-beta kinase phosphorylation of high sugar induction
1. experimental technique:
To be in exponential phase HBZY-1 cell is inoculated in T75 culture bottle, inoculum density about 80%, after cultivating 16-20h, serum starvation 24h, after giving rat by medicine of the present invention (preparing by embodiment method 1) gavage respectively, be separated Contained Serum and adopt SPE method and water soluble method to prepare Contained Serum extract (final concentration is respectively 1%, 2% and 4%), positive controls (2 μm of ol/LGF109203X (inhibitors of protein kinase C)), hatching 2h for 37 DEG C; After washing, add high concentration glucose again, final concentration is 30mmol/L, collecting cell after cultivation 4h, adds RIAP lysate (50mmol/LTris-HCl (pH7.4), 150mmol/LNaCl, 1%NP-40,1mmol/LEDTA, 0.25%sodiumdeoxycholate, 1mmol/LNa
3vO
4, 1mmol/LNaF, 1mmol/LPMSF and 2 μ g/mLLeupeptin) ice bath 30min, frozen-thawed four times, centrifugal, obtain cell lysate, adopt the method for westernblot to measure the expression of HBZY-1 cell PKC-β I, PKC-β II protein kinase.Method is as follows: BCA method measures total protein of cell amount, and adjustment each sample is to same concentrations, and SDS-PAGE is separated and is transferred on pvdf membrane, after the closed 2h of 5% defatted milk powder 37 DEG C, adds primary antibodie (1: 200) respectively, hatches 2h for 37 DEG C; Add corresponding two anti-igg-HRP (1: 3000) 37 DEG C again and hatch 1h.ECL luminescence reagent box, application gel imaging system chemiluminescence detection also carries out gray analysis by Imagelab system, with β-actin for internal reference.
2, result:
Concrete outcome is shown in Fig. 1 and 2, and result shows, high concentration glucose stimulates can cause Rat Mesangial PKC-β I and the increase of PKC-β II tyrosine phosphorylation; And after medicine Contained Serum extract of the present invention pretreatment, PKC-β I and PKC-β II protein kinase level obviously reduce, and there is obvious concentration dependence.
Embodiment 9 medicine of the present invention Contained Serum extract is on the impact of height sugared induced rat mesangial cell secretion of VEGF, TGF-β 1
1, experimental technique
Well-grown HBZY-1 cell is adopted to test.Be divided into following 8 groups: concentration group (final concentration 2%), Contained Serum high concentration group (4%) in Normal group (5.6mmol/LD-glucose), high sugared group (30mmol/LD-glucose), positive controls (2 μm of ol/LGF109203X (inhibitors of protein kinase C)), medicine of the present invention (preparing by embodiment method 1) Contained Serum low concentration group (final concentration 1%), Contained Serum, often organize duplicate hole.Respectively at administration process 24h, 48h collecting cell culture supernatant, utilize ELISA kit to detect VEGF, TGF-β 1 content in cells and supernatant, detection method is see test kit description.
2, experimental result:
1, ELISA testing result (Fig. 3) display: compared with normal control, after high concentration glucose (30mmol/L) stimulates different time, in culture supernatant, VEGF content obviously increases; And after the medicine Contained Serum of the present invention pretreatment of variable concentrations, in the HBZY-1 cells and supernatant that high sugar stimulates, VEGF content has and reduces in various degree.And positive control GF109203X also can obviously suppress high sugar to stimulate HBZY-1 emiocytosis VEGF to increase.Result shows that medicine of the present invention can effectively suppress the Rat Mesangial secretion of VEGF of high sugar induction to increase.
2, ELISA testing result (Fig. 4) display: compared with normal control, after high concentration glucose (30mmol/L) stimulates different time, in culture supernatant, TGF-β 1 content obviously increases; After the medicine Contained Serum extract of the present invention pretreatment of variable concentrations, in the HBZY-1 cells and supernatant that high sugar stimulates, TGF-β 1 content has and reduces in various degree.And positive control GF109203X also can obviously suppress high sugar to stimulate HBZY-1 emiocytosis TGF-β 1.Result shows that medicine of the present invention can obviously suppress the Rat Mesangial secretion TGF-β 1 of high sugar induction to increase.
Embodiment 10 pharmaceutical composition of the present invention is to the rat pharmacodynamic evaluation of diabetic nephropathy model
1. experimental technique
(institute of lab animals of Sichuan Academy of Medical Sciences provides to choose healthy male SD rat, the quality certification number: SCXK (river) 2008-24), SPF level, body weight 180 ~ 220g, each group of rat presses the single dose tail vein injection STZ (2% sodium citrate solution of PH4.2) of 55mg/kg, and rats in normal control group then gives equivalent 2% sodium citrate solution tail vein injection.After 48h tail vein blood survey blood glucose value, fasting glucose for three days on end >=16.7mmol/L, urine volume >=crude urine amount is defined as diabetic model rats.After 4 weeks treatment group respectively gavage give captopril (21mg/kgd) and medicine A (preparing by comparative example 1) (2.0g/kgd), medicine B (preparing by comparative example 2) (2.0g/kgd), medicine C (preparing by comparative example 3) (2.0g/kgd), medicine D (preparing by embodiment 2) (2.0g/kgd), medicine E (preparing by embodiment 1) (2.0g/kgd), medicine F (preparing by embodiment 3) (2.0g/kgd), blank group, model control group then every day gavage equal-volume distilled water, continuous 8 weeks of each group of administration.After drug treatment, the 2nd, 4,8 week metabolic cage collects record 24h urine volume, microtrabeculae measurement in chromatography glycolated hemoglobin, and fasting glucose content, detects 24h urine protein content with Coomassie Brilliant Blue; In last administration in the 8th week after 1 hour, femoral artery puncture gets blood, separation of serum, measure serum triglycerides (TG), T-CHOL (TC) content, serum creatinine (Scr), blood urea nitrogen (BUN), creatinine clearance rate (Ccr), take each group of rat kidney and body weight simultaneously, calculate kidney heavy (KWT) and kidney/body weight (KWT/BWT).
2. result
2.1 impacts on diabetic nephropathy model rat blood sugar, glycolated hemoglobin
Table 1 is on the impact of rat model fasting glucose, glycolated hemoglobin
Compare with blank group, ###P < 0.001; Compare with model control group,
*p < 0.05,
*p < 0.01,
* *p < 0.001
As seen from the results in Table 1, the each medicine group of the present invention all obviously can reduce the content of rat model blood glucose, glycolated hemoglobin, administration just obviously can reduce the content of blood glucose, glycolated hemoglobin for 2 weeks, 4 weeks, 8 weeks, and medicine E of the present invention significantly can reduce the content of blood glucose and glycolated hemoglobin.
2.2 impacts on diabetic nephropathy model rat 24h urine volume, urine albumen amount
Table 2 is on the impact of rat model 24h urine volume, urine albumen amount
Compare with blank group, ###P < 0.001; Compare with model control group,
*p < 0.05,
*p < 0.01,
* *p < 0.001;
As seen from the results in Table 2, the each medicine group of the present invention all can reduce the content of rat model 24h urine volume and urine protein in various degree, wherein medicine E of the present invention effect is comparatively obvious, and administration all has obvious effect (P < 0.05 ~ 0.001) for 2 weeks, 4 weeks, 8 weeks.
2.3 impacts on diabetic nephropathy model rat blood serum BUN, Scr, Ccr
Table 3 is on the impact of rat model serum BUN, Scr, Ccr
Compare with blank group, ###P < 0.001; Compare with model control group,
*p < 0.05,
*p < 0.01,
* *p < 0.001;
As shown in Table 3; the each medicine group of the present invention all can reduce rat model BUN, Scr content in various degree; reduce Ccr and then alleviate glomerule ultra filtration load, protection renal function, wherein medicine E of the present invention effect comparatively obviously (P < 0.01 ~ 0.001).
2.4 impacts on diabetic nephropathy model rat KWT, KWT/BWT
Table 4 is on the impact of rat model KWT, KWT/BWT
Compare with blank group, ###P < 0.001; Compare with model control group,
*p < 0.05,
*p < 0.01;
* *p < 0.001
As shown in Table 4; the each medicine group of the present invention all can reduce rat model KWT, KWT/BWT in various degree; have significant protective effect to the early stage kidney injury of rat model, wherein medicine E of the present invention effect comparatively obviously (P < 0.001).
2.5 impacts on diabetic nephropathy model rat TG, TC
Table 5 is on the impact of rat model serum TG, TC content
Compare with blank group, ###P < 0.001; Compare with model control group,
*p < 0.05,
*p < 0.01
As shown in Table 5, the each medicine group of the present invention all can reduce rat model serum TG, TC content in various degree, raise rat model blood fat and have obvious reducing effect effect, wherein medicine E of the present invention effect comparatively obviously (P < 0.01).
Embodiment 9, pharmaceutical composition of the present invention are to the hemodynamic pharmacodynamic evaluation of rat retina central artery
1, test method
Get normal male Wistar rat 300, with 50mg/kg dosage through the disposable injection streptozotocin of tail vein (sodium citrate buffer of 0.1mmol/L, pH4.4 is made into 1%STZ).Inject docking after 72 hours and get blood, measure fasting glucose, all fasting glucose >=16.7mmol/L persons are diabetes rat model, continue normal feedstuff and feed 3 months, measure rat retina hemodynamic parameter, if there is the exception of hemodynamic parameter, animal pattern can be defined as according to " guideline of clinical investigations that new Chinese medicine treatment of diabetic retinopathy becomes " and enter the sick Patients with Subclinical of sugar net.
Get in preventive experiment injection after STZ72 hour blood glucose rise to the diabetes rat model 70 of 16.7mmol/L, 5 groups are divided at random: model control group (equal-volume normal saline) with fasting glucose, positive controls (0.5g calcium dobesilate/kg body weight), medicine D (preparing by embodiment 2) (0.5g medicated powder/kg body weight), medicine E (preparing by embodiment 1) (0.5g medicated powder/kg body weight), medicine F (preparing by embodiment 3) (0.5g medicated powder/kg body weight), often organize 14, separately getting with batch normal rat 10 is Normal group (equal-volume normal saline).Each group of successive administration 24 weeks, Normal group and model control group give isopyknic normal saline.30mg/kg pentobarbital sodium ip anesthetized rat is adopted after last administration, measure the hemodynamics of every Rat Right eyes retina central artery (CRA) with Sequoia512 type color Doppler ultrasound, comprise peak systolic velocity (Max), End diastolic velocity (Min), mean blood flow velocity (TAMx).
Subclinical sugar futures net disease model rat 70 is got in curative test, 5 groups are divided at random: model control group (equal-volume normal saline), positive controls (0.5g calcium dobesilate/kg body weight), pharmaceutical composition of the present invention 2 groups (0.5g medicated powder/kg body weight), pharmaceutical composition of the present invention 5 groups (0.5g medicated powder/kg body weight), pharmaceutical composition of the present invention 6 groups (0.5g medicated powder/kg body weight) with hemodynamic index, often organize 14, separately getting with batch normal rat 10 is Normal group (equal-volume normal saline).Each group of successive administration 12 weeks, Normal group and model control group give isopyknic normal saline.30mg/kg pentobarbital sodium ip anesthetized rat is adopted after last administration, measure the hemodynamics of every Rat Right eyes retina central artery (CRA) with Sequoia512 type color Doppler ultrasound, comprise peak systolic velocity (Max), End diastolic velocity (Min), mean blood flow velocity (TAMx).
2, result of the test
Table 6 pharmaceutical composition is on the hemodynamic impact of diabetic retinopathy rat CRA (prevention group)
Note: model group compares with Normal group
△ △ △p < 0.001, administration group compares with model group
*p < 0.01
* *p < 0.001
Table 6 result shows, model group rats CRA blood flow velocity obviously reduces, the equal highly significant of Max, Min, TAMx is lower than the Normal group same period, reflection retinal blood infusate flow and blood supply wretched insufficiency, compare with model group, pharmaceutical composition of the present invention each dosage group rat CRA blood flow velocity obviously increases, and each dosage group is very significant.Result shows, pharmaceutical composition of the present invention can significantly improve diabetic retinal tissue in rat central artery blood perfusion and blood supply insufficiency, has significant preventive effect to diabetic retinopathy, and wherein pharmaceutical composition E is the most remarkable.
Table 7 pharmaceutical composition is on the diabetic sugar net hemodynamic impact of sick rat CRA (treatment group)
Note: model group compares with Normal group
△ △ △p < 0.001, administration group compares with model group
*p < 0.05
* *p < 0.001
Table 7 result shows, model group rats CRA blood flow velocity obviously reduces, the equal highly significant of Max, Min, TAMx is lower than the Normal group same period, reflection retinal blood infusate flow and blood supply wretched insufficiency, compare with model group, pharmaceutical composition of the present invention each dosage group rat CRA blood flow velocity obviously increases, and each dosage group is very significant.Result shows, and pharmaceutical composition of the present invention can significantly improve diabetic retinal tissue in rat central artery blood perfusion and blood supply insufficiency, has significant therapeutic effect to diabetic retinopathy, and wherein pharmaceutical composition E is the most remarkable.
Claims (7)
1. a pharmaceutical composition for prevention or treatment diabetic complication, is characterized in that active component is made up of the crude drug of following percentage by weight: the Radix Astragali 32 ~ 40%, Radix Pseudostellariae 10 ~ 15%, Fructus Ligustri Lucidi 16 ~ 20%, Fructus Lycii 12 ~ 18%, Hirudo 11 ~ 13%, Radix Et Rhizoma Rhei 5 ~ 8%.
2. pharmaceutical composition according to claim 1, is characterized in that described active component is made up of the crude drug of following percentage by weight: the Radix Astragali 36.14%, Radix Pseudostellariae 12.05%, Fructus Ligustri Lucidi 18.07%, Fructus Lycii 14.46%, Hirudo 12.05%, Radix Et Rhizoma Rhei 7.23%.
3. pharmaceutical composition according to claim 1 and 2, is characterized in that described diabetic complication is diabetic nephropathy.
4. pharmaceutical composition according to claim 1 and 2, is characterized in that described diabetic complication is diabetic renal papillary necrosis.
5. pharmaceutical composition according to claim 1 and 2, is characterized in that described pharmaceutical composition can make powder, tablet, capsule, pill, oral liquid, granule.
6. pharmaceutical composition according to claim 4, it is characterized in that described diabetic renal papillary necrosis is early diabetic retinopathy.
7. the pharmaceutical composition preparation method described in claim 1 or 2, is characterized in that:
1) Radix Astragali removing impurity, size separately, is cleaned, is run through, be cut into 2-4mm sheet, 60-80 DEG C of dry for standby;
2) Radix Pseudostellariae removing impurity, wash quickly is clean, is cut into 2-4mm sheet, 60-80 DEG C of dry for standby;
3) Fructus Ligustri Lucidi removing impurity and stalk leaf, clean, 60-80 DEG C of drying, the used time smashs to pieces;
4) Fructus Lycii removing impurity, picks carpopodium, for subsequent use after clean and tidy;
5) Hirudo, cleans, cutting, 60-70 DEG C of dry for standby;
6) Radix Et Rhizoma Rhei, removing impurity, clean, run through, cut straight sheet, thickness is 2-4mm, 60-80 DEG C of oven dry, and sieve goes chip for subsequent use;
Radix Et Rhizoma Rhei after being concocted by said method is pulverized, and cross 100 mesh sieves, get fine powder and carry out radiation sterilization, 2KGY/ hour, exposure time is for subsequent use after 3 hours; The Fructus Ligustri Lucidi that said method of learning from else's experience was concocted adds 6 times and measures 75% ethanol, reflux, extract, 2-4 time, each 1 hour, ethanol is reclaimed in alcohol extraction; The medicinal residues of Fructus Ligustri Lucidi and the Radix Astragali concocted through said method, Radix Pseudostellariae, Fructus Lycii, Hirudo add water the water of 6 times amount, decoct 2-4 time, each 2 hours, filter, merge Aqueous extracts, go to abandon medicinal residues, the concentrated solution after fried liquid and Fructus Ligustri Lucidi reclaim ethanol merges, under-0.015-0.030MPa, concentrating under reduced pressure, temperature is 80 DEG C, when to be concentrated into extractum relative density be 1.05-1.15, at 70 DEG C, spraying dry is dried cream powder, then mixes with aforementioned Radix Et Rhizoma Rhei for subsequent use and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110127492.7A CN102784237B (en) | 2011-05-17 | 2011-05-17 | Pharmaceutical composition for preventing or treating diabetic complications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110127492.7A CN102784237B (en) | 2011-05-17 | 2011-05-17 | Pharmaceutical composition for preventing or treating diabetic complications |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410538033.1A Division CN104352645A (en) | 2011-05-17 | 2011-05-17 | Pharmaceutical composition for preventing or treating diabetic complications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102784237A CN102784237A (en) | 2012-11-21 |
| CN102784237B true CN102784237B (en) | 2015-11-25 |
Family
ID=47149956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110127492.7A Active CN102784237B (en) | 2011-05-17 | 2011-05-17 | Pharmaceutical composition for preventing or treating diabetic complications |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102784237B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352645A (en) * | 2011-05-17 | 2015-02-18 | 成都康弘制药有限公司 | Pharmaceutical composition for preventing or treating diabetic complications |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104713953B (en) * | 2013-12-13 | 2017-06-30 | 成都康弘制药有限公司 | A kind of assay method of medicine finger-print |
| CN107281315B (en) * | 2016-04-11 | 2020-09-04 | 成都康弘制药有限公司 | Traditional Chinese medicine pellet and preparation method thereof |
| CN112190646B (en) * | 2020-11-19 | 2021-12-28 | 首都医科大学附属北京中医医院 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1347714A (en) * | 2001-05-21 | 2002-05-08 | 成都康弘制药有限公司 | Chinese herb. medicine composition for treating diabetes and nephropathy and its preparing method |
-
2011
- 2011-05-17 CN CN201110127492.7A patent/CN102784237B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1347714A (en) * | 2001-05-21 | 2002-05-08 | 成都康弘制药有限公司 | Chinese herb. medicine composition for treating diabetes and nephropathy and its preparing method |
Non-Patent Citations (3)
| Title |
|---|
| 渴络欣含药血清萃取物抑制高糖诱导的大鼠系膜细胞增殖及ERK1/ 2 磷酸化的研究;李健等;《四川大学学报（医学版）》;20101231;第41卷(第5期);780-783 * |
| 糖尿病视网膜病变的中医临床治疗进展;侯方;《北京中医药大学学报（中医临床版）》;20101130;第17卷(第6期);41-44 * |
| 近10年糖尿病视网膜病变中医药研究概况;李蓉等;《新疆中医药》;20051231;第23卷(第6期);84-87 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352645A (en) * | 2011-05-17 | 2015-02-18 | 成都康弘制药有限公司 | Pharmaceutical composition for preventing or treating diabetic complications |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102784237A (en) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106074971A (en) | A kind of hypoglycemic traditional Chinese medicine composition and preparation method and application | |
| CN106176918A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Radix Puerariae | |
| CN101590101A (en) | A kind of prescription and preparation technology who treats type and complication thereof | |
| CN102784237B (en) | Pharmaceutical composition for preventing or treating diabetic complications | |
| CN101647951B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN106421581A (en) | Biological traditional Chinese medicine for oral administration for treating diabetes and preparation method thereof | |
| CN104740054B (en) | A kind of pharmaceutical composition for preventing and treating myocardial ischemia and its production and use | |
| KR100712659B1 (en) | Herbal composition for treatment and prevention of diabetes and diabetic complications | |
| CN103800736B (en) | A kind of pharmaceutical composition treating hypertensive nephropathy and application thereof | |
| CN105343506A (en) | Method for preparing composition for treating type-2 diabetes | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN104352645A (en) | Pharmaceutical composition for preventing or treating diabetic complications | |
| CN108743885A (en) | A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications | |
| CN114767794B (en) | Traditional Chinese medicine for treating arterial plaque | |
| CN100387270C (en) | Traditional Chinese medicine formulation for treating and preventing diabetes and its angiopathy | |
| CN108379379A (en) | Chinese medicine composition for acute stage of gout | |
| CN108186799A (en) | Ground bone slender acanthopanax dissipates and preparation method | |
| CN101791351B (en) | Glipizide-containing traditional Chinese and western medicine composition | |
| CN101791350B (en) | Glibenclamide-containing traditional Chinese and western medicine composition | |
| CN107029124A (en) | It is a kind of to be used to treat Chinese medicine composition of essential hypertension and preparation method thereof | |
| CN106038812A (en) | Traditional Chinese medicine capsule for reducing blood fat and removing atherosclerotic plaque | |
| CN100496522C (en) | Medicinal composition containing propolis, preparation method and use thereof | |
| CN105194676A (en) | Medicine composition for treating hyperlipemia and preparation method of medicine composition | |
| CN105267632A (en) | Traditional Chinese medicine composition composition treating diabetic macular edema | |
| CN106138890A (en) | A kind of Chinese medicine preparation treating hypertension and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121121 Assignee: Sichuan Jishengtang Pharmaceutical Co., Ltd. Assignor: Kanghong Pharmaceutical Co., Ltd., Chengdu Contract record no.: 2017510000030 Denomination of invention: Medicinal composition for preventing and treating diabetic complications Granted publication date: 20151125 License type: Common License Record date: 20171018 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220525 Address after: No. 309, Tianfu East Road, Pengzhou Industrial Development Zone, Chengdu, Sichuan 611930 Patentee after: Sichuan Jishengtang Pharmaceutical Co.,Ltd. Address before: 610036 No. 36 Shu West Road, Chengdu, Sichuan, Jinniu District Patentee before: Chengdu Kanghong Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right |